An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients.
An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients.
复制标题
DOI：
10.1177/1534735417692097
复制
发表时间：
2018-06
影响因子：
2.9
通讯作者：
Shirahata S
中科院分区：
文献类型：
--
作者：
Takahashi H;Kawaguchi M;Kitamura K;Narumiya S;Kawamura M;Tengan I;Nishimoto S;Hanamure Y;Majima Y;Tsubura S;Teruya K;Shirahata S
背景。传统的抗癌疗法仍然会导致选择性根除困难以及伴随的副作用，从而降低患者的生活质量（QOL）。褐藻糖胶是从海藻中提取的，在基础研究中已经表现出广泛的生物活性，包括抗癌和抗炎特性。有望增强癌症患者的治疗效果并最大限度地减少副作用；然而，尽管岩藻依聚糖有潜在的好处，但使用岩藻依聚糖的临床试验却很少。因此，我们对晚期癌症患者进行了一项探索性临床研究，以检验岩藻依聚糖的功效，特别关注与生活质量评分相关的炎症。方法。我们对晚期癌症患者进行了一项前瞻性、开放性临床研究，使用岩藻依聚糖口服给药；招募了 20 名患有转移的晚期癌症患者，并给予 400 mL/d 岩藻依聚糖（10 mg/mL）至少 4 周。在治疗前、摄入岩藻依聚糖 2 周后和 4 周后监测炎症生物标志物，包括高敏 C 反应蛋白和各种细胞因子，以及生活质量评分。结果。摄入岩藻依聚糖两周后，主要促炎细胞因子，包括白细胞介素-1β (IL-1β)、IL-6 和肿瘤坏死因子-α (TNF-α) 显着减少。在研究期间，包括疲劳在内的生活质量得分几乎保持稳定，没有显着变化。单变量和多变量分析表明，IL-1β的反应性是一个重要的独立预后因素。结论。这是第一项提供岩藻依聚糖对晚期癌症患者抗炎作用证据的研究。在未来的研究中，需要进行更大规模的盲法对照试验来确定岩藻依聚糖作为癌症患者（尤其是接受化疗的患者）支持治疗的功效。
Background. Conventional anticancer therapies still cause difficulties with selective eradication and accompanying side effects that reduce patients’ quality of life (QOL). Fucoidan is extracted from seaweeds and has already exhibited broad bioactivities, including anticancer and anti-inflammatory properties, in basic studies. It is expected to enhance therapeutic efficacy and minimize side effects in cancer patients; however, despite its potential benefits, there are very few clinical trials using fucoidans. Therefore, we performed an exploratory clinical study for advanced cancer patients to examine the efficacy of fucoidans, especially focusing on inflammation in relation to QOL scores. Methods. We conducted a prospective, open-label clinical study for advanced cancer patients using fucoidans via oral administration; 20 advanced cancer patients with metastases were recruited and were given 400 mL/d fucoidan (10 mg/mL) for at least 4 weeks. Inflammatory biomarkers, including high-sensitivity C-reactive protein and various cytokines, and QOL scores were monitored before treatment, after 2 weeks, and after 4 weeks of fucoidan ingestion. Results. The main proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) were significantly reduced after 2 weeks of fucoidan ingestion. QOL scores, including fatigue, stayed almost stable without significant changes during the study period. The univariate and multivariate analyses revealed that the responsiveness of IL-1β was a significant independent prognostic factor. Conclusion. This is the first study providing evidence of the anti-inflammatory effects of fucoidans for advanced cancer patients. In future studies, larger blinded, controlled trials are required to establish the efficacy of fucoidan as supportive care for cancer patients, especially those undergoing chemotherapy.
登录
查看更多内容
从甲壳虫冈村甲壳虫中提取的口服岩藻糖素对肿瘤含量小鼠模型中肿瘤生长和存活时间的影响。
影响因子：
5.4
作者：
Azuma K;Ishihara T;Nakamoto H;Amaha T;Osaki T;Tsuka T;Imagawa T;Minami S;Takashima O;Ifuku S;Morimoto M;Saimoto H;Kawamoto H;Okamoto Y
通讯作者：
Okamoto Y
影响因子：
3.1
作者：
Gasiorowska A;Talar-Wojnarowska R;Kaczka A;Borkowska A;Czupryniak L;Małecka-Panas E
通讯作者：
Małecka-Panas E
影响因子：
5.4
作者：
de Jesus Raposo MF;de Morais AM;de Morais RM
通讯作者：
de Morais RM
影响因子：
9.2
作者：
Dinarello, Charles A.
通讯作者：
Dinarello, Charles A.
影响因子：
30.5
作者：
通讯作者：
--